Matrix metalloproteinases and their tissue inhibitors in malignancies of the female genital tract

Harefuah

Volumn 142, Issue 11, 2003, Pages 786-791+804

  Piura, B ^a   Rabinovich, A ^a   Huleihel, M ^a  

^a BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

Author keywords

Basement membrane; Cervical carcinoma; Extracellular matrix; Metalloproteinases; Ovarian carcinoma; Uterine carcinoma; Vulvar carcinoma

Indexed keywords

COLLAGENASE 3; GELATINASE A; GELATINASE B; MATRIX METALLOPROTEINASE; TISSUE INHIBITOR OF METALLOPROTEINASE; TUMOR MARKER;

ANGIOGENESIS; BASEMENT MEMBRANE; CANCER GROWTH; CANCER INVASION; CANCER PATIENT; CANCER SURVIVAL; EXTRACELLULAR MATRIX; FEMALE; FEMALE GENITAL TRACT CANCER; GENE OVEREXPRESSION; HIGH RISK PATIENT; HUMAN; METASTASIS; OVARY CARCINOMA; PROGNOSIS; PROTEIN DEGRADATION; PROTEIN FAMILY; REVIEW; SQUAMOUS CELL CARCINOMA; TREATMENT OUTCOME; UTERINE CERVIX CARCINOMA; UTERINE CERVIX CARCINOMA IN SITU; VULVA CARCINOMA;

FEMALE; GENITAL NEOPLASMS, FEMALE; HUMANS; MATRIX METALLOPROTEINASES; TISSUE INHIBITOR OF METALLOPROTEINASES; TUMOR MARKERS, BIOLOGICAL;

EID: 0242443924     PISSN: 00177768     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (32)

1. Overall CM & Lopez-Otin C, Strategies for MMP inhibition in cancer: innovations for the post-trial area. Nature Rev Cancer, 2002; 2: 657-672.
2. Sternlicht MD & Werb Z, How metalloproteinases regulate cell behavior. Annu Rev Cell Dev Biol, 2001; 17: 463-516.
3. Vu TH & Werb Z, Matrix metalloproteinases: effectors of development and normal physiology. Genes Dev, 2000; 14: 2123-2133.
4. Pepper MS, Role of the matrix metalloproteinase and plasminogen activator-plasmin systems in angiogenesis. Arterioscler Thromb Vasc Biol, 2001; 21: 1104-1117.
5. Huang LW, Garrett AP, Bell DA & al, Differential expression of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 protein and mRNA in epithelial ovarian tumors. Gynecol Oncol, 2000; 77: 369-376.
6. Davidson B, Reich R, Brener A & al, Ovarian carcinoma cells is serous effusions show altered MMP-2 and TIMP-2 mRNA levels. Eur J Cancer, 2001; 37: 2040-2049.
7. Kusano K, Miyaura C, Inada M & al, Regulation of matrix metalloproteinases (MMP-2, -3, -9, and -13) by interleukin-1 and interleukin-6 in mouse calvaria: association of MMP induction with bone resorption. Endocrinology, 1998; 139: 1338-1345.
8. Bode W, Fernandez-Catalan C, Tschesche H & al, Structural properties of matrix metalloproteinases. Cell Mol Life Sci, 1999; 55: 639-652.
9. Galboiz Y, Shapiro S, Lahat N & Miller A, Matrix metalloproteinases involvement in diseases of the central nervous system. Harefuah, 2001; 140: 329-333.
10. Furuya M, Ishikura H, Kawarada Y & al, Expression of matrix metalloproteinases and related tissue inhibitors in the cyst fluids of ovarian mucinous neoplasms. Gynecol Oncol, 2000; 78: 106-112.
11. Young TN, Rodriguez GC, Rinehart AR & al, Characterization of gelatinases linked to extracellular matrix invasion in ovarian adenocarcinoma: purification of matrix metalloproteinase 2. Gynecol Oncol, 1996; 62: 89-99.
12. Sela BA, Matrix metalloproteinases: promoters of tumor progression and invasiveness. IMAJ, 2002; 4: 280-282.
13. Boyd RS & Balkwill FR, MMP-2 release and activation in ovarian carcinoma: the role of fibroblasts. Br J Cancer, 1999; 80: 315-321.
14. Davidson B, Goldberg I, Gotlieb WH & al, High levels of MMP-2, MMP-9, MT1-MMP and TIMP-2 mRNA correlates with poor survival in ovarian carcinoma. Clin Exp Metastasis, 1999; 17: 799-808.
15. Nishikawa A, Iwasaki M, Akutagawa N & al, Expression of various matrix proteases and its family transcriptional factors in ovarian cancer cell line: correlation to invasive potential. Gynecol Oncol, 2000; 79: 256-263.
16. Sakata K, Shigemasa K, Nagai N & Ohama K, Expression of matrix metalloproteinases (MMP-2, MMP-9, MT1-MMP) and their inhibitors (TIMP-1, TIMP-2) in common epithelial tumors of the ovary. Int J Oncol, 2000; 17: 673-681.
17. Wu X, Li H, Kang L & al, Activated matrix metalloproteinase-2 - A potential marker of prognosis in epithelial ovarian cancer. Gynecol Oncol, 2002; 84; 126-134.
18. Iurlaro M, Loverro G, Vacca A & al, Angiogenesis extent and expression of matrix metalloproteinase -2 and -9 correlate with upgrading and myometrial invasion in endometrial carcinoma. Eur J Clin Invest, 1999; 29: 793-801.
19. Ueno H, Yamashita K, Azumano I & al, Enhanced production and activation of matrix metalloproteinase-7 (matrilysin) in human endometrial carcinomas. Int J Cancer, 1999; 84: 470-477.
20. Di Nezza L, Misajon A, Zhang J & al, Presence of active gelatinases in endometrial carcinoma and correlation of matrix metalloproteinase expression with increasing tumor grade and invasion. Cancer, 2002; 94: 1466-1475.
21. Garzetti GG, Ciavattini A, Lucarini G & al, Microinvasive cervical carcinoma and cervical intraepithelial neoplasia: biologic significance and clinical implications of 72-kDa metalloproteinase immunostaining. Gynecol Oncol, 1996; 61: 197-203.
22. Davidson B, Goldberg I, Kopolovic J & al, Expression of matrix metalloproteinase-9 in squamous cell carcinoma of the uterine cervix - clinicopathologic study using immunohistochemistry and mRNA in situ hybridization. Gynecol Oncol, 1999; 72: 380-386.
23. Davidson B, Goldberg I, Kopolovic J & al, MMP-2 and TIMP-2 expression correlates with poor prognosis in cervical carcinoma - a clinicopathologic study using immunohistochemistry and mRNA in situ hybridization. Gynecol Oncol, 1999; 73: 372-382.
24. Garzetti GG, Ciavattini A, Lucarini G & al, The 72-kDa metalloproteinase immunostaining in cervical carcinoma: relationship with lymph node involvement. Gynecol Oncol, 1996; 60: 271-176.
25. Garzetti GG, Ciavattini A, Lucarini G & al, Recurrence patterns in locally advanced cervical carcinoma: role of nodal status and 72-kDa metalloproteinase index. Gynecol Oncol, 1996; 61: 83-89.
26. Jeremias J & Witkin SS, Effect of human seminal fluid on production of messenger ribonucleic acid for metalloproteinase 2 and metalloproteinase 9 in cervical epithelial carcinoma cells. Am J Obstet Gynecol, 1999; 181: 591-595.
27. Johansson N, Vaalamo M, Grenman S & al, Collagenase-3 (MMP-13) is expressed by tumor cells in invasive vulvar squamous cell carcinoma. Am J Pathol, 1999; 154: 469-480.
28. Rasmussen HS & McCann PP, Matrix metalloproteinase inhibition as a novel anticancer strategy: a review with special focus on batimastat and marimastat. Pharmacol Ther, 1997; 75: 69-75.
29. Della Porta P, Soeltl R, Krell HW & al, Combined treatment with serine protease inhibitor aprotinin and matrix metalloproteinase inhibitor Batimastat (BB-94) does not prevent invasion of human esophageal and ovarian carcinoma cells in vivo. Anticancer Res, 1999; 19: 3809-3816.
30. Giavazzi R, Garofalo A, Ferri C & al, Batimastat, a synthetic inhibitor of matrix matalloproteinases, potentiates the antitumor activity of cisplatin in ovarian carcinoma xenografts. Clin Cancer Res, 1998; 4: 985-992.
31. Steward WP, Marimastat (BB2516): current status of development. Cancer Chemother Pharmacol, 1999; 43 (suppl): S56-60.
32. Heath EI, O'Reilly S, Humphrey R & al, Phase I trial of the matrix metalloproteinase inhibitor BAY12-9566 in patients with advanced solid tumors. Cancer Chemother Pharmacol, 2001; 48: 269-274.